

Supplementary Table 1. The effect of cetuximab-containing treatment between left and right sided-colorectal cancer.

Study	Treatment	Treatment line	PFS	OS
JACCRO CC-05106 study	XELOX/FOLFOX+Cetuximab	1 st line	11.1 m vs. 5.6 m (Left vs. Right)	36.2 m vs. 12.6 m
Moretto et.al.	Cetuximab+/-Irinotecan	Salvage	6.6 m vs. 2.3 m (Left vs. Right)	-
Chen et.al.	Cetuximab+/-Chemotherapy	Salvage	4.59 m vs. 2.75 (Left vs. Right)	12.62 m vs. 8.07 m
Lu et.al.	Standard Regimens+Cetuximab	1 st line	15.0 m vs. 5.3 m (Left vs. Right)	35.9 m vs. 14.4 m
CRYSTAL study	FOLFIRI+Cetuximab	1 st line	12.0 m vs 8.1 m (Left vs. Right)	27.7 m vs. 18.5
FIRE3 study	FOLFIRI+Cetuximab	1 st line	10.7 m vs. 7.6 m (Left vs. Right)	38.3 m vs. 18.3 m
The present Study	Cetuximab+/-Chemotherapy	1 st line	10.9 m vs. 7.1 m (Left vs. Right)	-
The present Study	Cetuximab+/-Chemotherapy	2 or more line	4.5 m vs. 5.8 m (Left vs. Right)	